Compare Johnson & Johnson (JNJ) vs Synopsys, Inc. (SNPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Synopsys, Inc. — how do they compare? Johnson & Johnson trades at $260.67 (market cap $626.09B), while Synopsys, Inc. trades at $412.2 (market cap $78.68B). The key difference: Johnson & Johnson is far larger — about 8× Synopsys, Inc.'s market cap, and Johnson & Johnson pays a 2.06% dividend while Synopsys, Inc. pays none. Which is the better fit depends on your goals.
| JNJ | SNPS | |
|---|---|---|
Market Cap | $626.09B | $78.68B |
Volume | 6,156,228 | — |
Sector | Health | Technology |
52-Week High | $267.24 | $625.80 |
52-Week Low | $172.78 | $372.33 |
Enterprise Value | $654.37B | $87.04B |
Dividend Yield | 2.06% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $260.88, down 0.36% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a net margin of 21.48% and ROE of 25.74%, though valuations like a P/E of 30.14 appear elevated. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a 64-year dividend growth streak, with analyst consensus leaning bullish.
Outlook remains positive with a consensus price target of $284.50, offering potential upside, but risks include legal challenges and high debt-to-asset ratio of 24.06% in 2025. Investors benefit from steady dividends and defensive positioning in healthcare, though valuation multiples may limit near-term gains amid economic uncertainty.
Synopsys (SNPS) trades at $413.78, up 0.51% on the day, with a bearish technical signal despite recent earnings beats. The stock shows high valuation ratios (P/E of 94.03, P/S of 8.68) but maintains strong gross margins of 73.47%. Recent news highlights AI-driven growth from the Ansys acquisition and partnerships with AMD and Microsoft, though cash flow trends show volatility with a net outflow of $1.01B in 2025.
Outlook remains positive with analyst consensus favoring Buy (82.76%) and a $551 price target, but risks include elevated valuation, competitive pressures, and integration challenges from acquisitions. Earnings growth and AI adoption in chip design are key catalysts, yet investors should monitor margin sustainability and debt levels amid expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →
